Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillanceFilipe Martins, Michel Obéid|Nature Reviews Clinical Oncology|2019Cited by 2.2k
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategyJohn B.A.G. Haanen, Michel Obéid, Marc S. Ernstoff et al.|Annals of Oncology|2020Cited by 230
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJohn B.A.G. Haanen, Michel Obéid, Yinghong Wang et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 164
Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R. Power, Anju Nohria, Charles Dolladille et al.|European Heart Journal|2025Cited by 34
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinomaVictor Joo, Michel Obéid|Nature Communications|2024Cited by 11